CCK-B receptor: Chemistry, molecular biology, biochemistry and pharmacology

Progress in Neurobiology

Volumn 58, Issue 4, 1999, Pages 349-379

  Noble, Florence ^a   Roques, Bernard P ^a  

^a Laboratoire de Pharmacochimie   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLECYSTOKININ B RECEPTOR; CHOLECYSTOKININ OCTAPEPTIDE;

BRAIN TISSUE; EMOTION; FEEDING BEHAVIOR; GASTROINTESTINAL TRACT; HORMONAL REGULATION; HORMONE RECEPTOR INTERACTION; HUMAN; MOTIVATION; NOCICEPTION; PRIORITY JOURNAL; PROTEIN LOCALIZATION; RECEPTOR AFFINITY; RECEPTOR DENSITY; REVIEW; TISSUE DISTRIBUTION;

ANIMALS; BRAIN CHEMISTRY; CHOLECYSTOKININ; GENE EXPRESSION; HUMANS; RECEPTOR, CHOLECYSTOKININ B; RECEPTORS, CHOLECYSTOKININ;

EID: 0032919177     PISSN: 03010082     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0301-0082(98)00090-2     Document Type: Review

References (287)

1. B receptor. Jpn. J. Pharmacol. 75:1997;33-42.
2. 1 receptor stimulation. Eur. J. Pharmac. 216:1992;157-166.
3. Baber N.S., Dourish C.T., Hill D.R. The role of CCK, caerulein, and CCK antagonists in nociception. Pain. 39:1989;307-328.
4. Baldwin J.M. The probable arrangement of the helices in G protein-coupled receptors. EMBO J. 12:1993;1693-1703.
5. Barrett R.W., Steffey M.E., Wolfram C.A.W. Type-A CCK receptors in CHP 212 neuroblastoma cells: evidence for association with G protein and activation of phosphoinositide hydrolysis. Mol. Pharmac. 35:1989;394-400.
6. Befort K., Tabbara L., Kling D., Maigret B., Kieffer B.L. Role of aromatic transmembrane residues of the δ-opioid receptor in ligand recognition. J. Biol. Chem. 271:1996;10161-10168.
7. Beinborn M., Lee Y.M., McBride E.W., Quinn S.M., Kopin A.S. A single amino acid of the cholecystokinin-B/gastrin receptor determines specificity for non peptide antagonists. Nature (Lond.). 362:1993;348-350.
8. Bellier B., McCort-Tranchepain I., Ducos B., DaNascimento S., Meudal H., Noble F., Garbay C., Roques B.P. Synthesis and biological properties of new constrained CCK-B antagonists: discrimination of two affinity states of the CCK-B receptor on transfected CHO cells. J. Med. Chem. 40:1997;3947-3956.
9. Bellier B., Da Nascimento S., Meudal H., Gincel E., Roques B.P., Garbay C. Novel constrained CCK-B dipeptoid antagonists derived from pipecolic acid. Bioorg. Med. Chem. Lett. 8:1998;1419-1424.
10. Ben Natan L., Chaillet P., Lecomte J.M., Marçais H., Uchida G., Costentin J. Involvement of endogenous enkephalins in the mouse "behavioral despair" test. Eur. J. Pharmac. 97:1984;301-304.
11. Benoliel J.J., Bourgoin S., Mauborgne A., Legrand J.C., Hamon M., Cesselin F. Differential inhibitory/stimulatory modulation of spinal CCK release by μ and δ opioid agonists, and selective blockade of μ-dependent inhibition by κ receptor stimulation. Neurosci. Lett. 124:1991;204-207.
12. Benoliel J.J., Mauborgne A., Bourgoin S., Legrand J.C., Hamon M., Cesselin F. Opioid control of the in vitro release of CCK-like material from the rat substantia nigra. J. Neurochem. 58:1992;916-922.
13. Berridge M.J., Irvine R.F. Inositol phosphates and cell signalling. Nature (Lond.). 341:1989;197-205.
14. Blommaert A.G., Weng J.H., Dorville A., McCort I., Ducos B., Durieux C., Roques B.P. Cholecystokinin peptidomimetics as selective CCK-B antagonists: design, synthesis, and in vitro and in vivo biochemical properties. J. Med. Chem. 36:1993;2868-2877.
15. Blommaert A.G. S., Dhôtel H., Ducos B., Durieux C., Goudreau N., Bado A., Garbay C., Roques B.P. Structure-based design of new constrained cyclic agonists of the cholecystokinin CCK-B receptor. J. Med. Chem. 40:1997;647-658.
16. Bock M.G., DiPardo R.M., Rittle K.E., Evans B.E., Freidinger R.M., Veber D.F., Chang R.S.L., Chen T.B., Keegan M.E., Lotti V.J. Cholecystokinin antagonists. Synthesis of asperlicin analogues with improved potency and water solubility. J. Med. Chem. 29:1986;1941-1945.
17. Bock M.G., DiPardo R.M., Evans B.E., Rittle K.E., Whitter W.L., Veber D.F., Anderson P.S., Freidinger R.M. Benzodiazepine gastrin and brain cholecystokinin receptor ligands: L-365,260. J. Med. Chem. 32:1989;13-16.
18. Bock M.G., DiPardo R.M., Mellin E.C., Newton R.C., Veber D.F., Freedman S.B., Smith A.J., Patel S., Kemp J.A., Marshall G.R., Fletcher A.E., Chapman K.L., Anderson P.S., Freidinger R.M. Second-generation benzodiazepine CCK-B antagonists. Development of sub-nanomolar analogues with selectivity and water solubility. J. Med. Chem. 37:1994;722-724.
19. Böhme A.G., Durieux C., Stutzmann J.M., Charpentier B., Roques B.P., Blanchard J.C. Electrophysiological studies with new CCK analogs: correlation with binding affinity on B-type receptors. Peptides. 10:1989;407-414.
20. Böhme A., Bertrand P., Pendley C., Doble A., Guyon C., Martin G., Stutzmann J.M., Dubroeucq M.C., Blanchard J.C. RP69758, novel cholecystokinin B type and gastrin antagonist. Naunyn-Schmiedeberg's Arch. Pharmac. 345:1992;R116.
21. Bolton G.L., Roth B.D., Trivedi B.K. Synthesis of conformationally constrained macrocyclic analogues of the potent and selective CCK-B antagonist CI-988. Tetrahedron. 49:1993;525-536.
22. Bourin M., Malinge M., Vasar E., Bradwejn J. Two faces of cholecystokinin: anxiety and schizophrenia. Fundam. Clin. Pharmac. 10:1996;116-126.
23. Bownds D. Site of attachment of retinal in rhodopsin. Nature (Lond.). 216:1967;1178-1181.
24. Bozarth M.A. Neural basis of psychomotor stimulant and opiate reward: evidence suggesting the involvement of a common dopaminergic system. Behav. Brain Res. 22:1986;107-116.
25. Bradwejn, J. (1995) Cholecystokinin and panic disorder. In: Cholecystokinin and Anxiety: from Neuron to Behavior, pp. 73-86. Eds. J. Bradwejn and E. Vasar. RB Landes Company, Austin.
26. Bradwejn J., de Montigny C. Benzodiazepines antagonize cholecystokinin-induced activation of rat hippocampal neurons. Nature. 312:1984;363-364.
27. Bradwejn J., Koszycki D., Shriqui C. Enhanced sensitivity to cholecystokinin tetrapeptide in panic disorder. Arch. Gen. Psychiat. 48:1991;603-610.
28. Bradwejn J., Koszycki D., Couetoux du Tertre A., van Megen H., den Boer J., Westenberg H. The panicogenic effects of cholecystokinin-tetrapeptide are antagonized by L-365,260, a central cholecystokinin receptor antagonist, in patients with panic disorder. Arch. Gen. Psychiat. 51:1994;486-493.
29. Branchereau P., Böhme G.A., Champagnat J., Morin-Surun M.P., Durieux C., Blanchard J.C., Roques B.P., Denavit-Saubié M. Cholecystokinin-A and cholecystokinin-B receptors in neurons of the brainstem solitary complex of the rats: pharmacological identification. J. Pharmac. Exp. Ther. 260:1992;1433-1440.
30. Cador M., Taylor J.R., Robbins T.W. Potentiation of the effects of reward-related stimuli by dopaminergic-dependent mechanisms in the nucleus accumbens. Psychopharmacology. 104:1991;377-385.
31. Camus A., Rose C., Schwartz J.C. Role of a serine endopeptidase in the hydrolysis of exogenous cholecystokinin by brain slices. Neuroscience. 29:1989;595-602.
32. Caron M.G., Lefkowitz R.J. Catecholamine receptors: structure, function, and regulation. Recent Prog. Horm. Res. 48:1993;277-290.
33. Chambers M.S., Hobbs S.C., Graham M.I., Watt A.P., Fletcher S.R., Baker R., Freedman S.B., Patel S., Smith A.J., Matassa V.G. Potent, selective, water-soluble benzodiazepine-based CCK-B receptor antagonists that contain lipophilic carboxylate surrogates. Bioorg. Med. Chem. Lett. 5:1995;2303-2308.
34. Chang R.S.L., Lotti V.J., Monaghan R.L., Birnbaum J., Stapley E.O., Goetz M.A., Albers-Schonberg G., Patchett A.A., Liesch J.M., Hensens O.D., Springer J.P. A potent nonpeptide cholecystokinin antagonist selective for peripheral tissues isolated from Aspergillus alliaceus. Science. 230:1985;177-179.
35. 3H]L-365,260: a new potent and selective brain cholecystokinin (CCK-B) and gastrin receptor antagonist radioligand. Mol. Pharmac. 35:1989;803-808.
36. Chapman V., Honoré P., Buritova J., Besson J.M. Cholecystokinin B receptor antagonism enhances the ability of a low dose of morphine to reduce c-Fos expression in the spinal cord of the rat. Neuroscience. 67:1995;731-739.
37. Charpentier B., Pélaprat D., Durieux C., Dor A., Reibaud M., Blanchard J.C., Roques B.P. Cyclic cholecystokinin analogues with high selectivity for central receptors. Proc. Natl Acad. Sci. U.S.A. 85:1988;1968-1972.
38. Charpentier B., Durieux C., Pélaprat D., Dor A., Reibaud M., Blanchard J.C., Roques B.P. Enzyme-resistant CCK analogs with high affinities for central receptors. Peptides. 9:1988;835-841.
39. 8 selective for central receptors. J. Med. Chem. 31:1989;1184-1190.
40. Chen I.W., Dorley J.M., Ramjit H.G., Pitzenberger S.M., Lin J.H. Physiological disposition and metabolism of L-365,260, a potent antagonist of brain cholecystokinin receptor, in laboratory animals. Drug Metab. Dispos. 20:1992;390-395.
41. ++ and elevation of inositol triphosphate by secretagogues in parietal and chief cells isolated from rabbit gastric mucosa. Biochim. Biophys. Acta. 888:1986;116-125.
42. Chini B., Mouillac B., Ala Y., Balestre M., Kallmeyer S., Hoflack J., Elands J., Hibert M., Manning M., Jard S., Barberis C. Tyr115 is the key residue for determining agonist selectivity in the V1a vasopressin receptor. EMBO J. 14:1995;2176-2182.
43. Chini B., Mouillac B., Balestre M.N., Trumpp-Kallmeyer S., Hoflack J., Hibert M., Andriolo M., Pupier S., Jard S., Barberis C. Two aromatic residues regulate the response of the human oxytocin receptor to the partial agonist arginine vasopressin. FEBS Lett. 397:1996;201-206.
44. 2 receptors. Mol. Pharmac. 43:1993;755-761.
45. Chuang C.N., Chen M.C.Y., Soll A.H. Gastrin-histamine interactions: direct and paracrine elements. Scand. J. Gastroenterol. 26:1991;95-102.
46. 4 derivatives. J. Med. Chem. 36:1993;166-172.
47. Crawley J.N. Cholecystokinin-dopamine interactions. Trends Pharmac. Sci. 12:1991;232-236.
48. Crawley J.N., Corwin R.L. Biological actions of cholecystokinin. Peptides. 15:1994;731-755.
49. Daugé, V. and Léna, I. (1998) CCK in anxiety and cognitive processes. Neurosci. Biobehav. Rev. in press.
50. Daugé, V. and Roques, B. P. (1995) Opioid and CCK systems in anxiety and reward. In: Cholecystokinin and Anxiety: from Neuron to Behavior, pp. 151-171. Eds. J. Bradwejn and E. Vasar. RG Landes Company, Austin.
51. Daugé V., Dor A., Féger J., Roques B.P. The behavioral effects of CCK-8 injected into the medial nucleus accumbens are dependent on the motivational state of the rat. Eur. J. Pharmac. 163:1989;25-32.
52. Daugé V., Böhme G.A., Crawley J.N., Durieux C., Stutzmann J.M., Féger J., Blanchard J.C., Roques B.P. Investigation of behavioral and electrophysiological responses induced by selective stimulation of CCKB receptors by using a new highly ptent CCK analog, BC 264. Synapse. 6:1990;73-80.
53. Daugé V., Derrien M., Blanchard J.C., Roques B.P. The selective CCK-B agonist, BC 264 injected in the antero-lateral part of the nucleus accumbens, reduces the spontaneous alternation behaviour of rats. Neuropharmacology. 31:1992;67-75.
54. Dellu F., Mayo W., Cherkaoui J., LeMoal M., Simon H. A two trial memory task with automated recording: study in young and aged rats. Brain Res. 588:1992;132-139.
55. Dellu F., Fauchey V., Le Moal M., Simon H. Extension of a new two-trial memory task in the rat: influence of environmental context on recognition processes. Neurobiol. Learn. Memory. 67:1997;112-120.
56. i by secretagogue stimulation of canine gastric parietal cells. Am. J. Physiol. 262:1992;G420-G426.
57. Derrien M., Noble F., Maldonado R., Roques B.P. Cholecystokinin-A but not cholecystokinin-B receptor stimulation induces endogenous opioid-dependent antinociceptive effects in the hot plate test in mice. Neurosci. Lett. 160:1993;193-196.
58. 8 in the posterior part of the nucleus accumbens. Brain Res. 617:1993;181-188.
59. Derrien M., Durieux M., Roques B.P. Antidepressant-like effects of CCK-B antagonists in mice: antagonism by naltrindole. Br. J. Pharmac. 111:1994;956-960.
60. Derrien M., McCort-Tranchepain I., Ducos B., Roques B.P., Durieux C. Heterogeneity of CCK-B receptors involved in animal models of anxiety. Pharmac. Biochem. Behav. 49:1994;133-141.
61. Derrien M., Daugé V., Blommaert A., Roques B.P. The selective CCK-B agonist, BC 264, impairs socially reinforced memory in the three-panel runway test in rats. Behav. Brain Res. 65:1994;139-146.
62. Dethloff L.A., De La Iglesia F.A. Cholecystokinin antagonists-A toxicologic properties. Drug Met. Rev. 24:1992;267-293.
63. Didier E., Horwell D.C., Pritchard M.C. Synthesis and CCK-B binding affinities of cyclic analogues of the potent and selective CCK-B antagonist CI-988. Tetrahedron. 48:1992;8471-8490.
64. Dietl M.M., Probst A., Palacios J.M. On the distribution of CCK receptor binding sites in the human brain: an autoradiographic study. Synapse. 1:1987;169-183.
65. 8 as radioligand. J. Neurosci. 4:1984;1021-1033.
66. Ding X.Q., Chen D., Hakanson R. Cholecystokinin-B/gastrin receptor ligands of the dipeptoids series act as agonists on histidine decarboxylase in rat stomach anterochromaffin-like cells. Pharmac. Toxicol. 76(Suppl. IV):1995;81.
67. Dixon R.A., Sigal I.S., Candelore M.R., Register R.B., Rands E., Strader C.D. Structural features required for ligand binding to the β-adrenergic receptor. EMBO J. 6:1987;3269-3275.
68. Du K., Nicole P., Couvineau A., Laburthe M. Aspartate 196 in the first extracellular loop of the human VIP1 receptor is essential for VIP binding and VIP-stimulated cAMP production. Biochem. Biophys. Res. Commun. 230:1997;289-292.
69. 8 analogues by rat brain slices. Neuropeptides. 7:1986;1-9.
70. Durieux C., Coppey M., Zajac J.M., Roques B.P. Occurrence of two cholecystokinin binding sites in guinea pig brain cortex. Biochem. Biophys. Res. Commun. 137:1986;1167-1173.
71. 3H]pBC 264, first highly potent and very selective radioligand for CCK-B receptors. Eur. J. Pharmac. 168:1989;269-270.
72. 3H]pBC 264. Eur. J. Pharmac. 209:1991;185-193.
73. 3H]SNF 8702. Mol. Pharmac. 41:1992;1089-1095.
74. Eissele R., Patberg H., Koop H., Krack W., Lorenz W., Thorburn A., McKnight T. Effect of gastrin receptor blockade on endocrine cells in rats during achlorhydria. Gastroenterology. 103:1992;1596-1601.
75. Fallon J.H., Hicks R., Loughlin S.E. The origin of cholecystokinin terminals in the basal forebrain of the rat: evidence from immunofluorescence and retrograde tracing. Neurosci. Lett. 37:1983;29-35.
76. Faris P.L., Komisaruk B.R., Watkins L.R., Mayer D.J. Evidence for the neuropeptide cholecystokinin as an antagonist of opiate analgesia. Science. 219:1983;310-312.
77. Faris P.L., McLaughlin C.L., Baile C.A., Olney J.W., Komisaruk B.R. Morphine analgesia potentiated but tolerance not affected by active immunization against cholecystokinin. Science. 226:1984;1215-1217.
78. Fincham C.I., Horwell D.C., Ratcliffe G.S., Rees D.C. The use of a proline ring as a conformational restraint in CCK-B receptor "dipeptoids" BioMed. Chem. Lett. 2:1992;403-406.
79. Fincham C.I., Higginbottom M., Hill D.R., Horwell D.C., O'Toole J.C., Ratcliffe G.S., Rees D.C., Roberts E. Amide bond replacements incorporated into CCK-B selective "dipeptoids" J. Med. Chem. 35:1992;1472-1484.
80. Fishburn C.S., Belleli D., David C., Carmon S., Fuchs S. A novel short isoform of the D3 dopamine receptor generated by alternative splicing in the third cytoplasmic loop. J. Biol. Chem. 268:1993;5872-5878.
81. Flood J.F., Morley J.E. Cholecystokinin receptors mediate enhanced memory retention produced by feeding and gastrointestinal peptides. Peptides. 10:1989;809-813.
82. Floresco S.B., Seamans J.K., Philipps A.G. A selective role for dopamine in the nucleus accumbens of the rat in random foraging but not delayed spatial win-shift-based foraging. Behav. Brain Res. 80:1996;161-168.
83. Fong T.M., Huang R.R.C., Strader C.D. Localization of agonist and antagonist binding domains of the human neurokinin-1 receptor. J. Biol. Chem. 267:1992;25664-25667.
84. Fong T.M., Cascieri M.A., Yu H., Bonsal A., Swain C., Strader C.D. Amino-aromatic interaction between histidine 197 of the neurokinin-1 receptor and CP-96,345. Nature (Lond.). 362:1993;350-353.
85. Fong T.M., Yu H., Cascieri M.A., Underwood D., Swain C.J., Strader C.D. The role of histidine 265 in antagonist binding to the neurokinin-1 receptor. J. Biol. Chem. 269:1994;2728-2732.
86. 1H NMR spectroscopy, fluorescence tranfer measurements and calculations. Biochemistry. 25:1986;3778-3787.
87. Fournié-Zaluski M.C., Coric P., Turcaud S., Lucas E., Noble F., Maldonado R., Roques B.P. Mixed-inhibitor-prodrug as a new approach towards systemically active inhibitors of enkephalin degrading enzymes. J.Med. Chem. 35:1992;2474-2481.
88. Galas M.C., Bernard N., Martinez J. Pharmacological studies on CCK-B receptors in guinea pig synaptoneurosomes. Eur. J. Pharmac. 226:1992;35-41.
89. Gall C., Lauterborn J., Burks D., Seroogy K. Co-localization of enkephalins and cholecystokinin in discrete areas of rat brain. Brain Res. 403:1987;403-408.
90. 3H]pentagastrin. Peptides. 4:1983;755-762.
91. Gibert-Rahola J., Tejedor P., Chover A.J., Payana M., Rodriguez M.M., Leonsegui I., Mellado M., Mico J.A., Maldonado R., Roques B.P. RB 38B, a selective endopeptidase inhibitor, induced several of escape deficits cause by inescapable shocks pretreatment in rats. Eur. J. Pharmac. 183:1990;2317-2325.
92. Giros B., Sokoloff P., Martres M.P., Riou J.F., Emorine L.J., Schwartz J.C. Alternative splicing directs the expression of two D2 dopamine receptor isoforms. Nature (Lond.). 342:1989;923-926.
93. 2 and derivatives: a new family of CCK antagonists. J. Med. Chem. 33:1990;3199-3204.
94. 2. Biopolymers. 34:1994;155-159.
95. Harhammer R., Schafer U., Henklein P., Ott T., Repke H. CCK-8-related C-terminal tetrapeptides: affinities for central CCKB and peripheral CCKA receptors. Eur. J. Pharmac. 209:1991;263-266.
96. Harper E.A., Roberts S.P., Shankley N.P., Black J.W. Analysis of variation in L-365,260 competition curves in radioligand binding assays. Br. J. Pharmac. 118:1996;1717-1726.
97. Harro J., Vasar E. Evidence that CCK-B receptors mediate the regulation of exploratory behaviour in the rat. Eur. J. Pharmac. 193:1991;379-381.
98. Harro J., Vasar E., Bradwejn J. Cholecystokinin in animal and human research on anxiety. Trends Pharmac. Sci. 14:1993;244-249.
99. Hendry S.H.C., Jones E.G. Morphology of synapses formed by cholecystokinin-immunoreactive axon terminals in regio superior of rat hippocampus. Neuroscience. 16:1985;57-68.
100. Hernando F., Fuentes J.A., Roques B.P., Ruiz-Gayo M. The CCK-B receptor antagonist, L-365,260, elicits antidepressant-type effects in the forced-swim test in mice. Eur. J. Pharmac. 261:1994;257-263.
101. Hernando F., Fuentes J.A., Fournié-Zaluski M.C., Roques B.P., Ruiz-Gayo M. Antidepressant-like effects of CCK-B receptor antagonists: involvement of the opioid system. Eur. J. Pharmac. 318:1996;221-229.
102. Higginbottom M., Hill D.R., Horwell D.C., Mostafai E., Suman-Chauhan N., Roberts E. Conformationally restricted analogues of the potent CCK-B antagonist CI-988. Bioorg. Med. Chem. 1:1993;209-217.
103. Higgins G.A., Nguyen P., Sellers E.M. Blockade of morphine conditioning by the CCK-A receptor antagonist devazepide. Eur. J. Pharmac. 197:1991;229-230.
104. Higgins G.A., Nguyen P., Sellers E.M. Morphine place conditioning is differentially affected by CCK-A and CCK-B receptor antagonists. Brain Res. 572:1992;208-215.
105. Higgins G.A., Joharchi N., Wang Y., Corrigall W.A., Sellers E.M. The CCK-A receptor antagonist devazepide does not modify opioid self-administration or drug discrimination: comparison with the dopamine antagonist haloperidol. Brain Res. 640:1994;246-254.
106. Hill D.R., Woodruff G.N. Differentiation of central cholecystokinin receptor binding sites using the non-peptide antagonist MK329 and L-365,260. Brain Res. 526:1990;276-283.
107. Hill D.R., Campbell N.J., Shaw T.M., Woodruff G.N. Autoradiographic localization and biochemical characterization of peripheral type CCK receptors in rat CNS using highly selective non-peptide CCK antagonists. J. Neurosci. 7:1987;2967-2976.
108. Hill D.R., Shaw T.M., Woodruff G.N. Species differences in the localization of "peripheral" type CCK receptors in rodent brain. Neurosci. Lett. 79:1987;286-298.
109. Hjorth S.A., Schambye H.T., Greenlee W.J., Schwartz T.W. Identification of peptide binding residues in the extracellular domains of the AT(1) receptor. J. Biol. Chem. 269:1994;30953-30959.
110. Höcker M., Hughes J.J., Fölsch U.R., Schmidt W.E. PD-135,158, a CCK-B/gastrin receptor antagonist stimulates rat pancreatic enzyme secretion as CCK-A receptor agonist. Eur. J. Pharmac. 242:1993;105-108.
111. Hökfelt T., Skirboll L.R., Rehfeld J.H., Gostein M., Markey K., Dann O. A subpopulation of mesencephalic dopamine neurons projecting to limbic areas contains a cholecystokinin-like peptide: evidence from immunohistochemistry combined with retrograde tracing. Neuroscience. 5:1980;2093-2142.
112. Hökfelt T., Cortés R., Schalling M., Ceccatelli S., Pelto-Huikko M., Persson H., Villar M.J. Distribution patterns of CCK and CCK mRNA in some neuronal and non-neuronal tissues. Neuropeptides. 19(Suppl.):1991;31-43.
113. B receptors in the rat brain. Mol. Cell. Neurosci. 4:1993;143-154.
114. Honoré P., Buritova J., Fournié-Zaluski M.C., Roques B.P., Besson J.M. Antinociceptive effects of RB 101, a complete inhibitor of enkephalin-catabolizing enzymes, are enhanced by a cholecystokinin type B receptor antagonist, as revealed by noxiously evoked spinal c-Fos expression in rats. J. Pharmac. Exp. Ther. 281:1997;208-217.
115. Horwell D.C., Hughes J., Hunter J.C., Pritchard M.C., Richardson R.S., Roberts E., Woodruff G.N. Rationally designed "dipeptoid" analogues of CCK. α-Methyltryptophan derivatives as highly selective and orally active gastrin and CCK-B antagonists with potent anxiolytic properties. J. Med. Chem. 34:1991;404-414.
116. Howbert, J.J., Lobb, K.L., Brown, R.F., Reel, J.K., Neel, D.A., Mason, N.R., Mendelsohn, L.G., Hodgkiss, J.P. and Kelly, J.S. (1992) A novel series of non-peptide CCK and gastrin antagonists: medicinal chemistry and electrophysiological demonstration of antagonism. In: Multiple Cholecystokinin Receptors Progress Toward CNS Therapeutic Targets, pp. 28-37. Eds. C.T. Dourish and S.J. Cooper. Oxford University Press, London.
117. Huang R.R.C., Yu H., Strader C.D., Fong T.M. Interaction of substance P with the second and seventh transmembrane domains of the neurokinin-1 receptor. Biochemistry. 33:1994;3007-3013.
118. Huang S.C., Fortune K.P., Wank S.A., Kopin A.S., Gardner J.D. Multiple affinity states of different cholecystokinin receptors. J. Biol. Chem. 269:1994;26121-26126.
119. 3H]PD 140376: a novel and highly selective antagonist radioligand for the cholecystokininB/gastrin receptor in guinea pig cerebral cortex and gastric mucosa. Mol. Pharmac. 43:1993;595-602.
120. Huppi K., Siwarski D., Pisegna J.R., Wank S. Chromosomal localization of the gastric and brain receptors for cholecystokinin (CCK-AR and CCK-BR) in human and mouse. Genomics. 25:1995;727-729.
121. Idänpään-Heikkilä J.J., Guilbaud G., Kayser V. Prevention of tolerance to the antinociceptive effects of systemic morphine by a selective cholecystokinin-B receptor antagonist in a rat model of peripheral neuropathy. J. Pharmac. Exp. Ther. 282:1997;1366-1372.
122. Idänpään-Heikkilä J.J., Perrot S., Guilbaud G., Kayser V. In mononeuropathic rats, the enhancement of morphine antinociception by L-365,260, a selective CCK-B receptor antagonist, depends on the dose of systemic morphine and stimulus characteristics. Eur. J. Pharmac. 325:1997;155-164.
123. Isenberg J.I., Walsh J.H., Grossman M.I. Zollinger-Ellison syndrome. Gastroenterology. 65:1973;140-165.
124. Ito M., Matsui T., Taniguchi T., Tsukamoto T., Murayama T., Arima N., Nakata H., Chiba T., Chihara K. Functinal characterization of human brain cholecystokinin-B receptor. A trophic effect of cholecystokinin and gastrin. J. Biol. Chem. 268:1993;18300-18305.
125. Itoh S., Lal H. Influences of cholecystokinin and analogues on memory processes. Drug Dev. Res. 21:1990;257-276.
126. Itoh S., Takashima A., Igano K., Inouye K. Memory effect of caerulein and its analogs in active and passive avoidance responses in the rat. Peptides. 10:1989;843-848.
127. Itoh S., Takashima A., Maeda Y. Memory impairments induced by peripherally administered cholecystokinin A-type receptor antagonists in rats. Drug Dev. Res. 26:1992;89-99.
128. Jagerschmidt A., Popovici T., O'Donohue M., Roques B.P. Identification and characterization of various cholecystokinin B receptor mRNA forms in rat brain tissue and partial determination of the cholecystokinin B receptor gene structure. J. Neurochem. 63:1994;1199-1206.
129. 100 in the second transmembrane domain of the cholecystokinin B receptor increases antagonist binding and reduces signal transduction. Mol. Pharmac. 48:1995;783-789.
130. A receptor antagonist selectivity. Eur. J. Pharmac. 296:1996;97-106.
131. Jagerschmidt A., Guillaume N., Roques B.P., Noble F. Binding sites and transduction process of the cholecystokinin B receptor: involvement of highly conserved aromatic residues of the transmembrane domains evidenced by site-directed mutagenesis. Mol. Pharmac. 53:1998;878-885.
132. Jensen, R. T., Huang, S. C., von Schrenck, T., Wank, S. A. and Gardner, J. D. (1990) Cholecystokinin receptor antagonists: ability to distinguish various classes of cholecystokinin receptors. In: Gastrointestinal Endocrinology: Receptors and Post-receptor Mechanisms, pp. 95-113. Eds. J. T. Thompson, C. M. Townsend, G. A. Greely, P. L. Rayford, C. W. Wooper, P. O. Singh and N. Rubin. Academic Press, New York.
133. Karnik S.S., Sackmann J.P., Chen H.A., Khorana G. Cysteine residues 180-187 are essential for the formation of the correct structure in bovine rhodopsin. Proc. Natl Acad. Sci. U.S.A. 85:1988;8459-8463.
134. Katsuura G., Itoh S. Passive avoidance deficit following intracerebroventricular administration of cholecystokinin tetrapeptide amide in rats. Peptides. 7:1986;809-814.
135. Kaupman K., Bruns C., Raulf H., Weber H.P., Mattes H., Lubbert H. Two amino acids, located in transmembrane domains VI and VII, determine the selectivity of the peptide agonist SMS 201-995 for the SSTR2 somatostatin receptor. EMBO J. 14:1995;727-735.
136. 26-33): evidence for CCK-B receptor heterogeneity. J. Pharmac. Exp. Ther. 255:1990;1278-1286.
137. B/gastrin receptor. Jpn. J. Pharmac. 71:1996;307-313.
138. 4 analogs: synthesis, and implication for the CCK-B receptor-bound conformation. J. Med. Chem. 38:1995;137-149.
139. Kopin A.S., Lee Y.M., McBride E.W., Miller L.J., Lu M., Lin H.Y., Kolakowski L.F., Beinborn M. Expression, cloning and characterization of the canine parietal cell gastrin receptor. Proc. natl Acad. Sci. U.S.A. 89:1992;3605-3609.
140. Kopin A.S., McBride E.W., Quinn S.M., Kolakowski L.F., Beinborn M. The role of the cholecystokinin-B/gastrin receptor transmembrane domains in determining affinity for subtype-selective ligands. J. Biol. Chem. 270:1995;5019-5023.
141. Kopin A.S., McBride E.W., Gordon M.C., Quinn S.M., Beinborn M. Inter- and intraspecies polymorphisms in the cholecystokinin-B/gastrin receptor alter drug efficacy. Proc. natl Acad. Sci. U.S.A. 94:1997;11043-11048.
142. Kramer M.S., Cutler N.R., Ballenger J.C., Patterson W.M., Mendels J., Chenault A., Shrivasta R., Matzura-Wolfe D., Lines C., Reines S. A placebo-controlled trial of L-365,260, a CCK-B antagonist, in panic disorder. Biol. Psychiat. 37:1995;462-466.
143. 8 and of the CCK-B selective agonist BC 264 on extracellular dopamine content in the anterior and posterior nucleus accumbens: a microdialysis study in freely moving rats. Brain Res. 628:1993;254-262.
144. Ladurelle N., Roques B.P., Daugé V. The transfer of rats from a familiar to a novel environment prolongs the increase of extracellular dopamine efflux induced by CCK8 in the posterior nucleus accumbens. J. Neurosci. 15:1995;3118-3127.
145. Ladurelle N., Keller G., Blommaert A., Roques B.P., Daugé V. The CCK-B agonist, BC 264, increases dopamine in the nucleus accumbens and facilitates motivation and attention after peripheral intraperitoneal injection in rats. Eur. J. Neurosci. 9:1997;1804-1814.
146. Ladurelle N., Sebret A., Garbay C., Roques B.P., Daugé V. Opposite effects of CCK-B agonists in grooming behavior in rats: further evidence for two CCK-B subsites. Br. J. Pharmac. 124:1998;1091-1098.
147. Lallement J.C., Oiry C., Lima-Leite A.C., Lignon M.F., Fulcrand P., Galleyrand J.C., Martinez J. Cholecystokinin and gastrin are not equally sensitive to GTPγS at CCK-B receptors: importance of the sulphated tyrosine. Eur. J. Pharmac. (Mol. Pharmac. Sec.). 290:1995;61-67.
148. Lam Y.K. T., Dai P., Zinc D.L., Smith A.J., Lee N.W., Freedman S., Salvatore M.J. New verginiamycin M-1 derivatives: synthesis cholecystokinin binding inhibitory and antimicrobial properties. J. Antibiot. 46:1993;623-630.
149. Lambert M., Bui N.D., Christophe J. Functional and molecular characterization of CCK receptors in the rat pancreatic acinar cell line AR4-2J. Regul. Pept. 322:1991;151-167.
150. Lamberts R., Creutzfeldt W., Stockmann F., Jacubaschke U., Mass S., Brunner G. Long-term omeprazole treatment in man: effects on gastric endocrine cell populations. Digestion. 39:1988;126-135.
151. Lanaud P., Popovici T., Normand E., Lemoine C., Bloch B., Roques B.P. Distribution of CCK mRNA in particular regions (hippocampus, periaqueductal grey and thalamus) of the rat by in situ hybridization. Neurosci. Lett. 104:1989;38-42.
152. Larsson H., Carlsson E., Ryberg B., Fryklund J., Wallmark B. Rat parietal cell function after prolonged inhibition of gastric acid secretion. Am. J. Physiol. 254:1988;G33-G39.
153. Lavigne G.J., Millington W.R., Mueller G.P. The CCK-A and CCK-B receptors antagonists devazepide and L-365,260 enhance morphine antinociception only in non-acclimated rats exposed to novel environment. Neuropeptides. 21:1992;119-129.
154. Lecomte J.M., Costentin J., Vlaiculescu A., Chaillet P., Marçais-Collado H., Llorens-Cortes C., Leboyer M., Schwartz J.C. Pharmacological properties of acetorphan, a parenterally active enkephalinase inhibitor. J. Pharmac. Exp. Ther. 237:1986;937-944.
155. Lee Y.M., Beinborn M., McBride E.W., Lu M., Kolakowski L.F., Kopin A.S. The human brain cholecystokinin-B/gastrin receptor. Cloning and characterization. J. Biol. Chem. 268:1993;8164-8169.
156. Lemaire M., Piot O., Roques B.P., Böhme A.G., Blanchard J.C. Evidence for an endogenous cholecystokininergic balance in social memory. NeuroReport. 3:1992;925-932.
157. Lemaire M., Barnéoud P., Böhme G.A., Piot O., Haun F., Roques B.P., Blanchard J.C. CCK-A and CCK-B receptors enhance olfactory recognition via distinct neuronal pathways. Psychopharmacology. 115:1994;435-440.
158. Léna I., Roques B.P., Durieux C. Dual modulation of dopamine release from anterior nucleus accumbens through cholecystokinin-B receptor subsites. J. Neurochem. 68:1997;162-168.
159. 2+ concentration in the human JURKAT T lymphocyte cell line. Eur. J. Pharmac. 245:1993;241-246.
160. Liu Y.F., Civelli O., Grandy D.K., Albert P.R. Differential sensitivity of the short and long human dopamine D2 receptor subtypes to protein kinase C. J. Neurochem. 59:1992;2311-2317.
161. Lloyd K.C. K., Raybould H.E., Taché Y., Walsh J.H. Role of gastrin, histamine, and acetylcholine in the gastric phase of acid secretion in anaesthetized rats. Am. J. Physiol. 262:1992;G747-G754.
162. Lo W.W.Y., Hughes J. Differential regulation of cholecystokinin- and muscarinic-receptor-mediated phosphoinositide turnover in flow 900 cells. Biochem. J. 251:1988;625-630.
163. Lotti V.J., Chang R.S. L. A new potent and selective non peptide gastrin antagonist and brain CCK-B ligand: L-365,260. Eur. J. Pharmac. 162:1989;273-280.
164. Luciani, N., Pommia, B., Noble, F. and Roques, B. P. Identification of various CCK-B receptor mRNA forms in rat gastric tissue: comparison with the forms characterized in the rat brain. Neurosci. Lett. (in preparation).
165. 2 with μ and δ opioid antinociception in the rat spinal cord. Neuropeptides. 16:1990;213-218.
166. Magous R., Galleyrand J.C., Bali J.P. Common or distinct receptors for gastrin and cholecystokinin in gastric mucosa? Biochim. Biophys. Acta. 1010:1989;357-362.
167. Maldonado R., Valverde O., Ducos B., Blommaert A.G., Fournié-Zaluski M.C., Roques B.P. Inhibition of morphine withdrawal by the association of RB 101, an inhibitor of enkephalin catabolism, and the CCK-B antagonist PD-134,308. Br. J. Pharmac. 114:1995;1031-1039.
168. 1A angiotensin II receptor is essential for its coupling to phospholipase C. J. Biol. Chem. 269:1994;20815-20818.
169. Marshall F.H., Barnes S., Hughes J., Woodruff G.N., Hunter J.C. Cholecystokinin modulates the release of dopamine from the anterior and posterior nucleus accumbens by two different mechanisms. J. Neurochem. 56:1991;917-922.
170. Mercer L.D., Beart P.M., Horne M.K., Finkelstein D.I., Carrive P., Paxinos G. On the distribution of cholecystokinin B receptors in monkey brain. Brain Res. 738:1996;313-318.
171. Merrit J.E., Taylor C.W., Rubin R.P., Putney J.W. Isomers of inositol triphosphate in exocrine pancreas. Biochem. J. 238:1985;825-829.
172. Migaud M., Durieux C., Viereck J., Soroca-Lucas E., Fournié-Zaluski M.C., Roques B.P. The in vivo metabolism of cholecystokinin (CCK-8) is essentially ensured by aminopeptidase A. Peptides. 17:1996;601-607.
173. Miller K.K., Lupica C.R. Morphine-induced excitation of pyramidal neurons is inhibited by cholecystokinin in the CA1 region of the rat hippocampal slice. J. Pharmac. Exp. Ther. 268:1994;753-761.
174. Million M.E., Léna I., Da Nascimento S., Noble F., Daugé V., Garbay C., Roques B.P. Development of new potent agonists able to interact with two postulated subsites of the cholecystokinin CCK-B receptor. Lett. Peptide Sci. 4:1997;407-410.
175. Miyake A. A truncated isoform of human CCK-B/gastrin receptor generated by alternative usage of a novel exon. Biochem. Biophys. Res. Commun. 208:1995;230-237.
176. Monsma F.J., McVittie L.D., Gerfen C.R., Mahan L.C., Sibley D.R. Multiple D2 dopamine receptors produced by alternative RNA splicing. Nature (Lond.). 342:1989;926-929.
177. de Montigny C. Cholecystokinin tetrapeptide induces panic-like attacks in healthy volunteers. Arch. Gen. Psychiat. 46:1989;511-517.
178. Montmayeur J.P., Borrelli E. Transcription mediated by a cAMP-responsive promoter element is reduced upon activation of dopamine D2 receptors. Proc. Natl Acad. Sci. U.S.A. 88:1991;3135-3139.
179. Moran T.H., Smith G.P., Hostetler A.M., McHugh P.R. Transport of cholecystokinin (CCK) binding sites in subdiaphragmatic vagal branches. Brain Res. 415:1987;149-152.
180. Moriarty P., Dimaline R., Thompson D.G., Dockray G.J. Characterization of cholecystokininA and cholecystokininB receptors expressed by vagal afferent neurons. Neuroscience. 79:1997;905-913.
181. Mutt V., Jorpes J.E. Structure of porcine cholecystokinin-pancreozymin. Eur. J. Biochem. 6:1968;156-162.
182. Nadzan, A. M., Garvey, D. S., Holladay, M. W., Shiosaki, K., Tufano, M. D., Shue, Y. K., Chung, J. Y. L., May, P. D., May, G. S., Lin, C. W., Miller, T. R., Witte, D. G., Bianchi, B. R., Wolfram, C. A. W., Burt, S. and Hutchins, G. W. (1991) Design of cholecystokinin analogs with high affinity and selectivity for brain receptors. In: Peptides, Chemistry and Biology, Proc. 12th American Peptide Symposium, pp. 101-102. Eds. J. A. Smith and J. E. Rivier. ESCOM, Leiden.
183. Nagata A., Ito M., Iwata N., Kuno J., Takano H., Minowa O., Chihara K., Matsui T., Noda T. G protein-coupled cholecystokinin-B/gastrin receptors are responsible for physiological cell growth of the stomach mucosa in vivo. Proc. Natl Acad. Sci. U.S.A. 93:1996;11825-11830.
184. Nichols M.L., Bian D., Ossipov M.H., Lai J., Porreca F. Regulation of morphine antiallodynic efficacy by cholecystokinin in a model of neurophatic pain in rats. J. Pharmac. Exp. Ther. 275:1995;1339-1345.
185. 8. Peptides. 10:1989;265-274.
186. Nishida A., Miyata K., Tsutsumi R., Yuki H., Akuzawa S., Kobayashi A., Kamato T., Ito H., Yamano M., Katuyama Y., Satoh M., Ohta M., Honda K. Pharmacological profile of (R)-1-[2,3-dihydro-1-(2′-methyl-phenacyl)-2-oxo-5-phenyl-1H-1,4- benzodiazepin-3-yl]-3-(3-methylphenyl)urea (YM022), a new potent and selective gastrin/cholecystokinin-B receptor antagonist, in vitro and in vivo. J. Pharmac. Exp. Ther. 269:1994;725-731.
187. Noble F., Soleilhac J.M., Soroca-Lucas E., Turcaud S., Fournié-Zaluski M.C., Roques B.P. Inhibition of the enkephalin-metabolizing enzymes by the first systemically active mixed inhibitor prodrug RB 101 induces potent analgesic responses in mice and rats. J. Pharmac. Exp. Ther. 261:1992;181-190.
188. Noble F., Derrien M., Roques B.P. Modulation of opioid analgesia by CCK at the supraspinal level: evidence of regulatory mechanisms between CCK and enkephalin systems in the control of pain. Br. J. Pharmac. 109:1993;1064-1070.
189. Noble F., Fournié-Zaluski M.C., Roques B.P. Unlike morphine, the endogenous enkephalins protected by RB 101 are unable to establish a conditioned place preference in mice. Eur. J. Pharmac. 230:1993;139-149.
190. Noble F., Blommaert A., Fournié-Zaluski M.C., Roques B.P. A selective CCK-B receptor antagonist potentiates μ-, but not δ-opioid receptor-mediated antinociception in the formalin test. Eur. J. Pharmac. 273:1995;145-151.
191. Noble, F., Da Nascimento, S. and Roques, B. P. Site directed mutagenesis experiments show that CCK-B receptor is coupled to two transduction pathways. Br. J. Pharmac., in preparation.
192. O'Dowd B., Hnatowich M., Caron M.G., Lefkowitz R.J., Bouvier M. Site-directed mutagenesis of the cytoplasmatic domains of the human β-2 adrenergic receptor. Localization of regions involved in G-protein-receptor coupling. J. Biol. Chem. 264:1988;7564-7569.
193. Ohtsuka T., Kotaki H., Nakayama N., Itezono Y., Shimma N., Kudoh T., Kuwahara T., Arisawa M., Yokose K. Tetronothiodin, a novel cholecystokinin type-B receptor antagonist produced by Streptomyces sp. NR0489 II. Isolation, characterization and biological activities. J. Antibiot. 46:1993;11-17.
194. 11]gastrin-(5-17) different in stimulating acid secretion in isolated rabbit gastric glands? Eur. J. Pharmac. 294:1995;511-519.
195. Olah M.E., Ren H., Ostrowski J., Jacobson K.A., Stiles G.L. Cloning, expression, and characterization of the unique bovine A1 adenosine receptor. J. Biol. Chem. 267:1992;10764-10770.
196. Olson G.A., Olson R.D., Kastin A.J. Endogenous opiates: 1994. Peptides. 16:1995;1517-1556.
197. Ovchinikov Y.A., Ablulajew N.G., Bogachuck A.S. Two adjacent cysteine residues in the C-terminal cytoplasmatic fragment of bovine rhodopsin are palmitoylated. FEBS Lett. 230:1988;1-5.
198. Padia J.K., Chilvers H., Daum P., Pinnock R., Suman-Chauhan N., Webdale L., Trivedi B.K. Design and synthesis of novel nonpeptide CCK-B receptor antagonists. Bioorg. Med. Chem. Lett. 7:1997;805-810.
199. Pang I.K., Sternweiss P.C. Purification of unique α subunits of GTP-binding regulatory proteins (G proteins) by affinity chromatography with immobilized βγ subunits. J. Biol. Chem. 265:1990;18707-18712.
200. Pearson R.K., Miller L.J., Hadac E.M., Powers S.P. Analysis of the carbohydrate composition of the pancreatic plasmalemmal glycoprotein affinity labeled by short probes for the cholecystokinin receptor. J. Biol. Chem. 262:1987;13850-13856.
201. 8. Neurochem. Int. 10:1987;495-508.
202. Pendley C.E., Fitzpatrick L.R., Capolino A.J., Davis M.A., Esterline N.J., Jakubowska A., Bertrand P., Guyon C., Dubroeucq M.C., Martin G.E. RP 73870, a gastrin/cholecystokinin-B receptor antagonist with potent anti-ulcer activity in the rat. J. Pharmac. Exp. Ther. 273:1995;1015-1022.
203. Pepin M.C., Yue S.Y., Roberts E., Wahlestedt C., Walker P. Novel "restoration of function" mutagenesis strategy to identify amino acids of the δ-opioid receptor involved in ligand binding. J. Biol. Chem. 272:1997;9260-9267.
204. Perrot S., Idänpään-Heikkilä J.J., Guilbaud G., Kayser V. The enhancement of morphine antinociception by a CCK-B receptor antagonist in the rat depends on the phase of inflammation and the intensity of carrageenin-induced hyperalgesia. Pain. 74:1998;269-274.
205. 5-enkephalinamide into the ventral tegmental area. Behav. Brain Res. 5:1982;225-229.
206. Ploeger G.E., Spruijt B.M., Cools A.R. Spatial localization in the Morris water maze in rats: acquisition is affected by intra-accumbens injections of the dopaminergic antagonist haloperidol. Behav. Neurosci. 108:1994;927-934.
207. 5-enkephalin-, and dynorphin A (1-8)-like materials in the spinal cord and dorsal root ganglia of adult rats: effetcs of dorsal rhizotomy and neonatal capsaicin. J. Neurochem. 55:1990;1122-1130.
208. Pohl M., Collin E., Benoliel J.J., Bourgoin S., Cesselin F., Hamon M. Cholecystokinin (CCK)-like material and CCK mRNA levels in the rat brain and spinal cord after acute or repeated morphine treatment. Neuropeptides. 21:1992;193-200.
209. Pommier, B., Da Nascimento, S., Dumont, S., Bellier, B., Million, E., Garbay, C., Roques, B. P. and Noble, F. The CCK-B receptor is coupled to two effector pathways through pertussis sensitive and insensitive G proteins. J. Neurochem. submitted.
210. Probst W.C., Snyder L.A., Schuster D.I., Brosius J., Sealfon S.C. Sequence alignement of the G protein-coupled receptor superfamily. DNA Cell Biol. 11:1992;1-20.
211. Pu S.F., Zhuang H.X., Lu Z.B., Wu X.R., Han J.S. Cholecystokinin gene expression in rat amygdaloid neurons. Normal distribution and effect of morphine tolerance. Mol. Brain Res. 21:1994;183-189.
212. Rasmussen K., Czachura J.F., Stockton M.E., Howbert J.J. Electrophysiological effects of diphenylpyrazolidinone cholecystokinin-B and cholecystokinin-A antagonists on midbrain dopamine neurons. J. Pharmac. Exp. Ther. 264:1992;480-488.
213. Rattray M., De Belleroche J. Morphine action on cholecystokinin octapeptide release from rat periaqueductal grey slices: sensitization by naloxone. Neuropeptides. 10:1987;189-200.
214. Rehfeld J.F., Holst J.J., Jensen S.L. The molecular nature of vascularly released cholecystokinin from the isolated perfused porcine duodenum. Regul. Pept. 3:1982;15-28.
215. Roberts G.W., Woodhams P.L., Polak J.M., Crow T.J. Distribution of neuropeptides in the limbic system of the rat: the amygdaloid complex. Neuroscience. 7:1982;99-131.
216. Roche S., Magous R. Gastrin and CCK-8 induce inositol 1,4,5-trisphosphate in rabbit gastric parietal cells. Biochim. Biophys. Acta. 1014:1989;313-318.
217. Roche S., Bali J.P., Magous R. Involvement of a pertussis toxin-sensitive G protein in the action of gastrin on gastric parietal cells. Biochim. Biophys. Acta. 1055:1990;287-294.
218. Roche S., Bali J.P., Galleyrand J.C., Magous R. Characterization of a gastrin-type receptor on rabbit gastric parietal cells using L-365,260 and L-364,718. Am. J. Physiol. 260:1991;G182-G188.
219. Roche S., Gusdinar T., Bali J.P., Magous R. Biphasic kinetics of inositol 1,4,5-triphosphate accumulation in gastrin-stimulated parietal cells. Effects of pertussis toxin and extracellular calcium. FEBS Lett. 282:1991;147-151.
220. Rodriguez R.E., Sacristan M.P. In vivo release of CCK-8 from the dorsal horn of the rat: inhibition by DAGOL. FEBS Lett. 250:1989;215-217.
221. Rodriguez M., Lignon M.F., Galas M.C., Amblard M., Martinez J. Cyclic cholecystokinin analogues that are highly selective for rat and guinea pig central cholecystokinin receptors. Mol. Pharmac. 38:1990;333-341.
222. Roques, B. P. and Noble, F. (1995) Dual inhibitors of enkephalin-degrading enzymes (neutral endopeptidase 24.11 and aminopeptidase N) as potential new medications in the management of pain and opioid addiction. In: Discovery of Novel Opioid Medications, pp. 104-145. Eds. R. S. Rapaka and H. Sorer. NIDA Res. Monograph. U.S. Government Printing Office, Pittsburgh, PA.
223. Roques B.P., Noble F. Association of enkephalin catabolism inhibitors and CCK-B antagonists: a potential use in the management of pain and opioid addiction. Neurochem. Res. 21:1996;1395-1409.
224. Roques B.P., Noble F., Daugé V., Fournié-Zaluski M.C., Beaumont A. Neutral endopeptidase 24.11: structure, inhibition, and experimental and clinical pharmacology. Pharmac. Rev. 45:1993;87-146.
225. Rose C., Vargas F., Facchinetti P., Bourgeat P., Bambal R.B., Bishop P.B., Chan S.M. T., Moore A.N. J., Ganellin C.R., Schwartz J.C. Characterization and inhibition of a cholecystokinin-inactivating serine peptidase. Nature (Lond.). 380:1996;403-409.
226. 27-33 a highly potent CCK8 analogue. Peptides. 6:1985;415-420.
227. Ruiz-Gayo M., Delay-Goyet P., Durieux C., Corringer P.J., Baamonde A., Gacel G., Roques B.P. Investigation of opioid and cholecystokinin central receptors after peripheral injection of selective and enzyme-resistant peptides. J. Control. Release. 13:1990;147-155.
228. 3H]pBC264: evidence for a physiological regulation of CCKergic systems by endogenous enkephalins. J. Neurochem. 59:1992;1805-1811.
229. Sandvik A.K., Waldum H.L. CCK-B (gastrin) receptor regulates gastric histamine release and acid secretion. Am. J. Physiol. 260:1991;G925-G928.
230. Sandvik A.K., Waldum H.L., Kleveland P.M., Schulzesognen B. Gastrin produces an immediate and dose-dependent histamine release preceding acid secretion in the totally isolated, vascularly perfused rat stomach. Scand. J. Gastroenterol. 22:1987;803-810.
231. Schäfer M., Zhou L., Stein C. Cholecystokinin inhibits peripheral opioid analgesia in inflamed tissue. Neuroscience. 82:1998;603-611.
232. Schwartz T.W., Rosenkilde M.M. Is there a "lock" for all agonist "keys" in 7TM receptors? Trends Pharmac. Sci. 17:1996;213-216.
233. Sekiguchi R., Moroji T. A comparative study on characterization and distribution of CCK binding sites among the rat, mouse and guinea pig brain. Brain Res. 399:1986;271-281.
234. Semple G., Ryder H., Kendrick D.A., Szelke M., Ohta M., Satoh M., Nishida A., Akuzawa S., Miyata K. Synthesis and biological activity of 1-alkylcarbonyl methyl analogues of YM 022. Bioorg. Med. Chem. Lett. 6:1996;51-54.
235. Semple G., Ryder H., Kendrick D.A., Szelke M., Ohta M., Satoh M., Nishida A., Akuzawa S., Miyata K. Synthesis and biological activity of 5-heteroaryl benzodiazepines: analogues of YM 022. Bioorg. Med. Chem. Lett. 6:1996;55-59.
236. Semple G., Ryder H., Rooker D.P., Batt A.R., Kendrick D.A., Szelke M., Ohta M., Satoh M., Nishida A., Akusawa S., Miyata K. (3R)-N-(1-(tert-butylcarbonylmethyl)-2,3-dihydro-2-oxo-5-(2-pyridyl)-1H-1,4- benzodiazepin-3-yl)-N′-(3-(methylamino)phenyl)urea (YF476): a potent and orally active gastrin/CCK-B antagonist. J. Med. Chem. 40:1997;331-341.
237. 3 cells. J. Neurochem. 62:1994;1352-1356.
238. 4. In: Peptides: Chemistry, Structure and Biology. Proc. 11th American Peptide Symposium, pp. 978-980. Eds. J. E. Rivier and G. R. Marshall. ESCOM, Leiden.
239. Silvente-Poirot S., Wank S.A. A segment of five amino acids in the second extracellular loop of the cholecystokinin-B receptor is essential for selectivity of the peptide agonist gastrin. J. Biol. Chem. 271:1996;14698-14706.
240. Smadja C., Maldonado R., Turcaud S., Fournié-Zaluski M.C., Roques B.P. Opposite role of CCK-A and CCK-B receptors in the modulation of endogenous enkephalin antidepressant-like effects. Psychopharmacology. 120:1995;400-408.
241. Smadja C., Ruiz F., Coric P., Fournié-Zaluski M.C., Roques B.P., Maldonado R. CCK-B receptors in the limbic system modulate the antidepressant-like effects induced by endogenous enkephalins. Psychopharmacology. 132:1997;227-236.
242. Soll A.H., Amirian D.A., Thomas L.P., Reedy T.J., Elashoff J.D. Gastrin receptors on isolated canine parietal cells. J. Clin. Invest. 73:1984;1434-1440.
243. Song I., Brown D.R., Wiltshire R.N., Gantz I., Trent J.M., Yamada T. The human gastrin/cholecystokinin type B receptor gene: alternative splice donor site in exon 4 generates two variant mRNAs. Proc. Natl Acad. Sci. U.S.A. 90:1993;9085-9089.
244. Spengler D., Waeber C., Pantaloni C., Holsboer F., Bockaert J., Seeburg P.H., Journot L. Differential signal transduction by five splice variants of the PACAP receptor. Nature (Lond.). 365:1993;170-174.
245. Stanfa L.C., Dickenson A.H. Cholecystokinin as a factor in the enhanced potency of spinal morphine following carrageenin inflammation. Br. J. Pharmac. 108:1993;967-973.
246. Stanfa L., Dickenson A., Xu X.J., Wiesenfeld-Hallin Z. Cholecystokinin and morphine analgesia. Trends Pharmac. Sci. 15:1994;65-66.
247. Strader C.D., Sigal I.S., Dixon R.A. Genetic approaches to the detrmination of structure-function relationships of G protein-coupled receptors. Trends Pharmac. Sci. 10(Suppl.):1989;26-30.
248. 3H]PD 140376. Regulatory Peptides. 65:1996;37-43.
249. Taghzouti K., Louilot A., Herman J.P., LeMoal M., Simon H. Alternation behaviour, spatial discrimination and reversal disturbances following 6-OHDA lesions in the nucleus accumbens of the rat. Behav. Neural. Biol. 44:1985;354-363.
250. Taghzouti, K., Léna, I., Dellu, F., Roques, B. P., Daugé, V. and Simon, H. (1998) Cognitive enhancing effects in young and old rats of pBC 264, a selective CCK-B receptor agonist. Psychopharmacology in press.
251. Talkad V.D., Fortune K.P., Pollo D.A., Shah G.N., Wank S.A., Gardner J.D. Direct demonstration of three different states of the pancreatic cholecystokinin receptor. Proc. Natl Acad. Sci. U.S.A. 91:1994;1868-1872.
252. Tejedor-Real R., Mico J.A., Maldonado R., Roques B.P., Gibert-Rahola J. Effect of a mixed (RB 38A) and selective (RB 38B) inhibitors of enkephalin-degrading enzymes on a model of depression in the rat. Biol. Psychiat. 34:1993;100-107.
253. Tejedor-Real R., Mico T.P., Maldonado R., Roques B.P., Gibert-Rahola J. Implication of endogenous opioid system in the learned helplessness model of depression. Pharmac. Biochem. Behav. 52:1995;145-152.
254. Trivedi B.K., Padia J.K., Holmes A., Rose S., Wright D.S., Hinton J.P., Prithchard M.C., Eden J.M., Kneen C., Webdale L., Suman-Chauhan N., Boden P., Singh L., Field M.J., Hill D. Second generation "peptoid" CCK-B receptor antagonists: identification and development of N-(adamantyloxycarbonyl)-α-methyl-(R)-tryptophan derivative (CI-1015) with an improved pharmacokinetic profile. J. Med. Chem. 41:1998;38-45.
255. 2+ oscillations in pancreatic acini. Biochem. Biophys. Res. Commun. 194:1993;1194-1202.
256. Tsunoda Y., Takeda H., Asaka M., Nakagaki I., Sasaki S. Initial and sustained calcium mobilizations in the parietal cell during stimulations with gastrin, inositol triphosphate, phorbol ester and exogenous diacylglycerol. FEBS Lett. 232:1988;83-89.
257. 1A subtype. G protein-coupled receptor. Chem. Biol. 1:1994;211-221.
258. Valverde O., Maldonado R., Fournié-Zaluski M.C., Roques B.P. Cholecystokinin B antagonists strongly potentiate antinociception mediated by endogenous enkephalins. J. Pharmac. Exp. Ther. 270:1994;77-88.
259. Valverde O., Blommaert A.G. S., Fournié-Zaluski M.C., Roques B.P., Maldonado R. Weak tolerance to the antinociceptive effect induced by the association of a peptidase inhibitor and a CCK-B antagonist. Eur. J. Pharmac. 286:1995;79-93.
260. Valverde O., Fournié-Zaluski M.C., Roques B.P., Maldonado R. The CCK-B antagonist PD-134,308 facilitates rewarding effects of endogenous enkephalins but does not induce place preference in rats. Psychopharmacology. 123:1996;119-126.
261. Verge V.M. K., Wiesenfeld-Hallin Z., Hökfelt T. Cholecystokinin in mammalian primary sensory neurons and spinal cord: in situ hybridization studies on rat and monkey spinal ganglia. Eur. J. Neurosci. 5:1993;240-250.
262. B and neurotensin receptors. Br. J. Pharmac. 121:1997;310-316.
263. Wang J.B., Johnson P.S., Wu J.M., Wang W.F., Uhl G.R. Human κ opiate receptor second extracellular loop elevates dynorphin's affinity for human μ/κ chimeras. J. Biol. Chem. 269:1994;25966-25969.
264. Wank S.A. Cholecystokinin receptors. Am. J. Physiol. 269:1995;G628-G646.
265. Wank S.A., Harkins R.T., Jensen R.T., Shapira H., de Weerth A., Slattery T. Purification, molecular cloning, and functional expression of the cholecystokinin receptor from rat pancreas. Proc. Natl Acad. Sci. U.S.A. 89:1992;3125-3129.
266. Wank S.A., Pisegna J.R., De Weerth A. Brain and gastrointestinal cholecystokinin receptor family: structure and functional expression. Proc. Natl Acad. Sci. U.S.A. 89:1992;8691-8695.
267. Wank S.A., Pisegna J.R., de Weerth A. Cholecystokinin receptor family: molecular cloning, structure and functional expression in rat, guinea pig and human. Ann. NY Acad. Sci. 713:1994;49-66.
268. 4 bioactive conformation. Reg. Pept. 65:1996;3-9.
269. 2 derivatives. Bioorg. Med. Chem. 4:1996;563-573.
270. Wennogle L., Wysowskyj H., Steel D.J., Petrack B. Regulation of central cholecystokinin recognition sites by guanyl nucleotides. J. Neurochem. 50:1988;954-963.
271. Wiesenfeld-Hallin Z., Xu X.J., Hughes J., Horwell D.C., Hökfelt T. PD134308, a selective antagonist of cholecystokinin type B receptor, enhances the analgesic effect of morphine and synergistically interacts with intrathecal galanin to depress spinal nociceptive reflexes. Proc. Natl Acad. Sci. U.S.A. 87:1990;7105-7109.
272. Williams G.V., Goldman-Rakic P.S. Modulation of memory fields by dopamine D1 receptors in prefrontal cortex. Nature (Lond.). 376:1995;572-575.
273. Williams J.A., Gryson K.A., McChesney D.J. Brain CCK receptors: species differences in regional distribution and selectivity. Peptides. 7:1986;292-296.
274. Willner P. Animal models of depression: an overview. Pharmac. Ther. 45:1990;425-455.
275. Woodruff G.N., Hughes J. Cholecystokinin antagonists. A. Rev. Pharmac. Toxic. 31:1991;469-501.
276. Woodruff G.N., Hill D.R., Boden P., Pinnock R., Singh L., Hughes J. Functional role of brain CCK receptors. Neuropeptides. 19(Suppl.):1991;45-56.
277. Xu X.J., Puke M.J. C., Verge V.M. K., Wiesenfeld-Hallin Z., Hughes J., Hökfelt T. Up-regulation of cholecystokinin in primary sensory neurons is associated with morphine insensitivity in experimental neuropathic pain in the rat. Neurosci. Lett. 152:1993;129-132.
278. Xu X.J., Hökfelt T., Hughes J., Wiesenfeld-Hallin Z. The CCK-B antagonist CI 988 enhances the reflex-depressive effect of morphine in axotomized rats. NeuroReport. 5:1994;718-720.
279. Xu X.J., Hao J.X., Seiger A., Hughes J., Hökfelt T., Wiesenfeld-Hallin Z. Chronic pain-related behaviors in spinally injured rats: evidence for functional alterations of the endogenous cholecystokinin and opioid systems. Pain. 56:1994;271-277.
280. Xu X.J., Elfvin A., Hao J.X., Fournié-Zaluski M.C., Roques B.P., Wiesenfeld-Hallin Z. CI-988, an antagonist of the cholecystokinin-B receptor, potentiates endogenous opioid-mediated antinociception at spinal level. Neuropeptides. 31:1997;287-291.
281. Yoshida H., Tsunoda Y., Owyang C. Cholecystokinin peptides stimulate pancreatic secretion by multiple signal transduction pathways. Am. J. Physiol. 273:1997;G735-G747.
282. Yu M.J., Trasher K.J., McCowan J.R., Mason N.R., Mendelsohn L.G. Quinazolinone cholecystokinin-B receptor ligands. J. Med. Chem. 34:1991;1505-1508.
283. Yule D.I., Tseng M.J., Williams J.A., Logsdon C.D. A cloned CCK-A receptor transduces multiple signals in response to full and partial agonists. Am. J. Physiol. 265:1993;G999-G1004.
284. Zarbin M.A., Wamsley J.K., Innis R.B., Kuhar M.J. Cholecystokinin receptors: presence and axonal flow in the rat vagus nerve. Life Sci. 29:1981;697-705.
285. Zhang L.J., Lu X.Y., Han J.S. Influences of cholecystokinin octapeptide on phosphoinositide turnover in neonatal-rat brain cells. Biochem. J. 285:1992;847-850.
286. Zhou Y., Sun Y.H., Zhang Z.W., Han J.S. Accelerated expression of cholecystokinin gene in the brain of rats rendered tolerant to morphine. NeuroReport. 3:1992;1121-1123.
287. Zhou Y., Sun Y.H., Zhang Z.W., Han J.S. Increased release of immunoreactive cholecystokinin octapeptide by morphine and potentiation of μ-opioid analgesia by CCK-B receptor antagonist L-365,260 in rat spinal cord. Eur. J. Pharmac. 234:1993;147-154.